AI-Designed Drugs? Isomorphic Labs Prepares for First Human Trials

Isomorphic Labs, a spin-off from Google DeepMind, is on the verge of a significant advancement in medicine. The company is preparing to initiate human clinical trials for drugs crafted entirely through Artificial Intelligence. This development could mark a pivotal moment in pharmaceutical research if successful.

The AlphaFold AI system, developed by DeepMind, laid the foundation for Isomorphic Labs. This advanced AI can accurately predict protein structures and model their interactions with molecules like DNA and drugs. Such capabilities enable researchers to design medicines swiftly and precisely.

AI-Driven Drug Design

Colin Murdoch, president of Isomorphic Labs and DeepMind's chief business officer, highlighted the company's progress. In an interview with Fortune, he stated, "There are people sitting in our office in London, collaborating with AI to design drugs for cancer right now." He further mentioned that the next major step involves moving into clinical trials.

Since its inception in 2021, Isomorphic Labs has collaborated with leading pharmaceutical companies such as Novartis and Eli Lilly. These partnerships have been instrumental in supporting existing drug programs and advancing research in oncology and immunology.

Funding and Future Prospects

In April 2025, Isomorphic Labs secured $600 million in funding to accelerate its mission. This financial boost aims to expedite the drug discovery process while reducing costs and enhancing success rates. The current drug development process is costly and time-consuming, with only a 10% success rate.

Murdoch envisions a future where AI can design drugs with just a click of a button. If this vision becomes reality, it could transform medicine development and offer quicker cures for various diseases. The company's advancements signify a crucial step towards harnessing AI's full potential in healthcare.

The progress made by Isomorphic Labs brings us closer to realising the dream of curing all diseases. By leveraging AI technology, they aim to make this ambitious goal achievable.